You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥(01672.HK):皮下注射PD-L1抗體ASC22 IIa期臨試完成首例乙型肝炎患者給藥
格隆匯 08-17 08:04

格隆匯 8 月 17日丨歌禮制藥-B(01672.HK)發佈公告,公司的ASC22IIa期臨牀試驗完成首例乙型肝炎患者給藥。ASC22是同類首創皮下注射的PD-L1抗體。

ASC22(恩沃利單抗)IIa期臨牀試驗是一項單劑量遞增研究,採用三種皮下給藥劑量(0.3、1.0和2.5mg/kg),以探討ASC22(恩沃利單抗)在慢性乙型肝炎患者中的安全性和有效性(ClinicalTrials.gov註冊號:NCT04465890)。公司相信,由於慢性乙型肝炎病毒感染中的T細胞衰竭為影響免疫耐受性的重要因素,因此阻斷PD-1/PD-L1路徑或為改善特定T細胞功能並實現慢性乙型肝炎臨牀治癒的有效免疫療法。

除ASC22外,公司還有其他三種用於治療慢性乙型肝炎的藥品或在研藥物,即市售藥品派羅欣®及兩種內部研發的臨牀實驗前或待臨牀實驗在研藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account